98%
921
2 minutes
20
Transient receptor potential vanilloid 1 (TRPV1), a ligand-gated cation channel, is a receptor for vanilloids on sensory neurons and is also activated by capsaicin, heat, protons, arachidonic acid metabolites, and inflammatory mediators on neuronal or non-neuronal cells. However, the role of the TRPV1 receptor in pro-inflammatory cytokine secretion and its potential regulatory mechanisms in lipopolysaccharide (LPS)-induced inflammation has yet to be entirely understood. To investigate the role and regulatory mechanism of the TRPV1 receptor in regulating LPS-induced inflammatory responses, bone marrow-derived macrophages (BMDMs) harvested from wild-type (WT) and TRPV1 deficient (Trpv1) mice were used as the cell model. In WT BMDMs, LPS induced an increase in the levels of tumor necrosis factor-α, IL-1β, inducible nitric oxide synthase, and nitric oxide, which were attenuated in Trpv1 BMDMs. Additionally, the phosphorylation of inhibitor of nuclear factor kappa-Bα and mitogen-activated protein kinases, as well as the translocation of nuclear factor kappa-B and activator protein 1, were all decreased in LPS-treated Trpv1 BMDMs. Immunoprecipitation assay revealed that LPS treatment increased the formation of TRPV1-Toll-like receptor 4 (TLR4)-cluster of differentiation 14 (CD14) complex in WT BMDMs. Genetic deletion of TRPV1 in BMDMs impaired the LPS-triggered immune-complex formation of TLR4, myeloid differentiation protein 88, and interleukin-1 receptor-associated kinase, all of which are essential regulators in LPS-induced activation of the TLR4 signaling pathway. Moreover, genetic deletion of TRPV1 prevented the LPS-induced lethality and pro-inflammatory production in mice. In conclusion, the TRPV1 receptor may positively regulate the LPS-mediated inflammatory responses in macrophages by increasing the interaction with the TLR4-CD14 complex and activating the downstream signaling cascade.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254490 | PMC |
http://dx.doi.org/10.1538/expanim.23-0148 | DOI Listing |
Physiol Res
August 2025
Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.
Paclitaxel (PTX), a commonly used chemotherapeutic, frequently leads to chemotherapy-induced peripheral neuropathy (CIPN), characterized by persistent pain and neuronal hypersensitivity. While its effects on peripheral nerves are well-documented, paclitaxel also influences central nervous system pathways, particularly spinal synaptic transmission, through Toll-like receptor 4 (TLR4) activation and subsequent sensitization of transient receptor potential vanilloid 1 (TRPV1) receptors. In this study, we used an in vitro model of paclitaxel-induced neuropathic pain to investigate the role of glial activation in TRPV1 receptor function.
View Article and Find Full Text PDFExp Neurol
August 2025
Department of Psychological and Brain Sciences, Texas A&M University, USA. Electronic address:
Traumatic brain injury (TBI) is a major cause of death and disability in the United States. In many cases, TBI is accompanied by additional tissue damage (polytrauma) that will engage pain (nociceptive) sensory fibers. Prior work using an animal model (rats) has shown that nociceptive stimulation after a spinal cord injury (SCI) fosters hemorrhage at the site of injury and amplifies secondary tissue loss.
View Article and Find Full Text PDFInt Immunopharmacol
August 2025
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; National Key Laboratory of Macromolecular Drug Development and Manufacturing, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Oujiang Laboratory (Zhejiang Lab
Medicine strategies focused on reducing secondary injury and delaying spinal cord injury (SCI) progression by targeting M1 microglial polarization remain uncommon. Galanin (GAL), a neuroendocrine peptide, is encoded by the GAL gene. In this study, we demonstrated that administration of recombinant human GAL peptides in a mouse model of SCI significantly elevated transient receptor potential vanilloid type 1 (TRPV1) receptor expression at the injury site through GALR2, substantially alleviating inflammation during the early stages post-injury.
View Article and Find Full Text PDFPain Manag
August 2025
Department of Perioperative Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Clinical investigations of resiniferatoxin (RTX) analgesia are currently ongoing for several human pain indications. RTX is an agonist of the TRPV1 receptor cation ion channel which is activated by capsaicin, heat, and inflammatory conditions. RTX injection at peripheral sites of pain generation will produce a chemo-inactivation of local nerve terminals and axons and block the transmission of nociceptive signals to spinal cord.
View Article and Find Full Text PDFScand J Pain
January 2025
AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.
Background: The transient receptor potential cation channel subfamily V1 (TRPV1) receptor is an important factor in pain transmission. The present Phase 2a study investigated the effect on evoked pain and safety of a topically administered TRPV1-antagonist (ACD440 Gel) in patients with chronic peripheral neuropathic pain (PNP).
Methods: This was an exploratory, randomized, placebo-controlled double-blind crossover study in patients with probable or definite PNP demonstrating sensory hypersensitivity, assessed as evoked pain on suprathreshold sensory stimulation, i.